603392.SHG Beijing Wantai Biological Pharmacy Enterprise Co Ltd
- Market cap
- CNY 32.2B
- P/E
- -
- P/B
- 2.66x
- ROE
- -2.6%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603392.SHG undervalued?
Graham numberThe Graham number of Beijing Wantai Biological Pharmacy Enterprise Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Wantai Biological Pharmacy Enterprise Co Ltd fundamental analysis
No fundamental analysis for Beijing Wantai Biological Pharmacy Enterprise Co Ltd yet.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests for detection of Hepatitis virus infections; P-85 Ab for nasopharyngeal cancer scr…
Full company profileBeijing Wantai Biological Pharmacy Enterprise Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 844M | 950M | 983M | 1.18B | 2.35B | 5.75B | 11.2B | 5.51B | 2.25B | 1.82B | 2.16B |
| Gross Profit | 609M | 655M | 699M | 833M | 1.88B | 4.90B | 9.99B | 4.43B | 1.38B | 897M | 1.37B |
| Operating Income | 131M | 179M | 289M | 218M | 775M | 2.33B | 5.60B | 1.40B | 93.8M | -426M | -220M |
| EBITDA | 152M | 157M | 186M | 230M | 809M | 2.33B | 5.40B | 1.58B | -65.1M | -129M | -309M |
| Net Income | 148M | 150M | 293M | 209M | 677M | 2.02B | 4.74B | 1.25B | 106M | -398M | -308M |
| EPS | 0.14 | 0.15 | 0.27 | 0.19 | 0.57 | 1.64 | 3.79 | 0.99 | 0.08 | -0.31 | -0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 1.45B | 1.66B | 1.81B | 2.16B | 3.50B | 7.05B | 16.2B | 15.7B | 14.7B | 14.0B | 13.6B |
| Total Liabilities | 495M | 757M | 444M | 584M | 923M | 2.48B | 3.66B | 2.83B | 2.24B | 2.01B | 1.76B |
| Shareholders' Equity | 889M | 878M | 1.35B | 1.56B | 2.55B | 4.47B | 12.3B | 12.7B | 12.3B | 11.9B | 11.6B |
| Cash & Short-term Investments | 309M | 341M | 427M | 342M | 761M | 1.46B | 7.20B | 6.27B | 4.90B | 2.43B | 2.52B |
| Total Debt | - | 218M | 21.0M | 21.0M | 77.7M | 287M | 278M | 209M | 279M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 129M | 147M | 208M | 273M | 468M | 1.68B | 4.13B | 1.60B | 355M | 89.8M | - |
| Capital Expenditure | 131M | 215M | 246M | 162M | 390M | 1.05B | 930M | 1.16B | 887M | 805M | 469M |
| Free Cash Flow | -1.86M | -67.7M | -37.8M | 111M | 77.8M | 634M | 3.20B | 378M | -532M | -715M | -585M |
| Ratios | |||||||||||
| ROE | 16.7% | 17.1% | 21.7% | 13.4% | 26.5% | 45.3% | 38.4% | 9.8% | 0.9% | -3.4% | -2.6% |
| ROA | 10.2% | 9.1% | 16.1% | 9.6% | 19.3% | 28.7% | 29.2% | 7.9% | 0.7% | -2.8% | -2.3% |
| Net Profit Margin | 17.6% | 15.8% | 29.8% | 17.6% | 28.8% | 35.2% | 42.3% | 22.6% | 4.7% | -21.9% | -14.2% |
| Debt to Equity | - | 0.25x | 0.02x | 0.01x | 0.03x | 0.06x | 0.02x | 0.02x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 3, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.28M | 0.00 | - |
| 2024 | CNY 410M | 0.31 | 386.1% |
| 2023 | CNY 904M | 0.72 | 72.5% |
| 2022 | CNY 121M | 0.10 | 2.6% |
| 2021 | CNY 108M | 0.09 | 5.4% |
| 2020 | CNY 1.65M | 0.00 | 0.2% |
| 2019 | CNY 1.04M | 0.00 | 0.5% |
| 2018 | CNY 6.29M | 0.01 | 2.1% |
| 2017 | CNY 4.56M | 0.00 | 3.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 5, 2023.
Who owns Beijing Wantai Biological Pharmacy Enterprise Co Ltd
- Insiders 82.09%
- Institutions 2.38%
- Public & others 15.53%
- Shares outstanding 1.26B
- Free float 269M
Beijing Wantai Biological Pharmacy Enterprise Co Ltd company profile
- Company name
- Beijing Wantai Biological Pharmacy Enterprise Co Ltd
- Ticker
- 603392.SHG
- ISIN
- CNE100004090
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,116
- Fiscal year end
- December
- Address
- No. 31, Kexue Yuan Road, Beijing, China, 102206
- Phone
- 86 10 5952 8888
- Website
- ystwt.com
About Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests for detection of Hepatitis virus infections; P-85 Ab for nasopharyngeal cancer screening; and TB-IGRA for large population screening. It also provides diagnostic assays, such as high-value Hepatitis B core antibody tests, Hepatitis E Urine tests, Hepatitis D virus detection, IL-6, HIV 4th generation CLIA, Helicobacter pylori antibody, gastrin-17, and soluble transferrin receptor assays; and enzyme-linked immunosorbent assay (ELISA), colloidal gold, molecular, clinical laboratory quality control products, and bioactive materials for various infectious diseases, such as HIV, Hepatitis, Tuberculosis, and Influenza A/B. In addition, the company offers core diagnostic solutions comprising chronic disease management, integrated Hepatitis E screening and prevention, full lifecycle women's health programs, and intelligent laboratory services. Further, it provides medical instruments, diagnostic tests, quality control products, bioactive materials, and diagnostics solutions; and HPV, Hepatitis E, and Nasal Spray COVID-19 vaccines. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a subsidiary of Yangshengtang Co., Ltd.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd management
4- Ms. Zhiming JiangGM & Director · born 1973
- Mr. Yun LuCFO & Director · born 1989
- Mr. Pan HuirongDeputy General Manager · born 1978
- Gangsheng LiAccounting Supervisor